Product Description
Mechanisms of Action: METAP2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Egypt | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Lebanon | Malaysia | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Russia | Serbia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Baxter Healthcare
Company Location: DEERFIELD IL 60015
Company CEO: José E. Almeida
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Hong Kong, Korea, New Zealand, Russia, Thailand, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Cholestasis, Intrahepatic
Phase 2: Hepatitis B, Chronic|Intestinal Diseases|Muscle Weakness
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SeND Home | P2 |
Recruiting |
Muscle Weakness |
2025-06-30 |
|
| RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |
| RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |
| RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |
| 2006-7041-83/hah | P2 |
Not yet recruiting |
Intestinal Diseases|Hepatitis B, Chronic |
2020-03-31 |